Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights and Forecasts, 2017-2030

MLA

“Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights and Forecasts, 2017-2030.” Plus Company Updates, 5 Aug. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.631722154&authtype=sso&custid=ns315887.

APA

Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights and Forecasts, 2017-2030. (2020, August 5). Plus Company Updates.

Chicago

Plus Company Updates. 2020. “Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights and Forecasts, 2017-2030,” August 5. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.631722154&authtype=sso&custid=ns315887.